"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu

NCT ID: NCT03097952

Last Updated: 2017-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis B virus (HBV) infection remains one of the most serious health problems worldwide. Patients with chronic HBV infection are at an increased risk for developing hepatic cirrhosis, hepatocellular carcinoma and even death. Although some predictive factors of the outcome of chronic HBV infection were identified, more precisely determine the factors which are associated with the outcome in non-selected patients with chronic HBV infection are still needed. The investigators purpose is to constitute a observational cohort of non-selected Chinese patients to create a database of epidemiological, clinical, biological, virological, immunologic and therapeutic parameters, in order to determine factors associated with the outcome of chronic HBV infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic HBV infection (defined as HBsAg positive for at least 6 months)

Exclusion Criteria

* Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) and/or hepatitis D virus (HDV)
* History of liver transplantation
* History of hepatocellular carcinoma (HCC)
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chao Wu

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Third Hospital of Changzhou

Changzhou, Jiangsu, China

Site Status RECRUITING

Huai'an No.4 People's Hospital

Huai'an, Jiangsu, China

Site Status RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

Site Status RECRUITING

Nanjing Jiangbei People's Hospital

Nanjing, Jiangsu, China

Site Status RECRUITING

Suqian People's Hospital

Suqian, Jiangsu, China

Site Status RECRUITING

The Fifth People's Hospital of Suzhou

Suzhou, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chao Wu, M.D., Ph.D

Role: CONTACT

Phone: 86-25-83105890

Email: [email protected]

Rui Huang, M.D., Ph.D.

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Longgen Liu

Role: primary

Biao Zhang

Role: primary

Chao Wu, M.D., Ph.D.

Role: primary

Rui Huang, M.D., Ph.D.

Role: backup

Jie Yin

Role: primary

Huaping Shao

Role: primary

Chuanwu Zhu

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Wang J, Zhu L, Zhang Z, Zhang S, Pan Y, Li Y, Cao F, Jiang C, Fan T, Xiong Y, Liu J, Chen Y, Yin S, Tong X, Zhu C, Liu X, Li J, Wu C, Huang R. Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase. Virol J. 2024 Jun 4;21(1):127. doi: 10.1186/s12985-024-02368-0.

Reference Type DERIVED
PMID: 38835029 (View on PubMed)

Yao R, Lu S, Xue R, Wang J, Qiu Y, Chen Y, Liu J, Zhu L, Zhan J, Jiang S, Yin S, Tong X, Ding W, Li J, Zhu C, Huang R, Wu C. NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study. Ann Hepatol. 2024 Jan-Feb;29(1):101155. doi: 10.1016/j.aohep.2023.101155. Epub 2023 Sep 24.

Reference Type DERIVED
PMID: 37742745 (View on PubMed)

Wang J, Liu J, Liu Y, Xue R, Zhan J, Jiang S, Wang L, Yan X, Xiong Y, Xia J, Yin S, Tong X, Chen Y, Li J, Huang R, Wu C. Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease. Hepatol Res. 2023 Mar;53(3):184-195. doi: 10.1111/hepr.13854. Epub 2022 Nov 21.

Reference Type DERIVED
PMID: 36317959 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NJDTID-001

Identifier Type: -

Identifier Source: org_study_id